Ivar Roots
#150,466
Most Influential Person Now
Ivar Roots's AcademicInfluence.com Rankings
Ivar Rootsbiology Degrees
Biology
#11213
World Rank
#14594
Historical Rank
Computational Biology
#237
World Rank
#238
Historical Rank
Genetics
#1201
World Rank
#1302
Historical Rank
Molecular Biology
#1707
World Rank
#1736
Historical Rank
Download Badge
Biology
Ivar Roots's Degrees
- PhD Molecular Biology University of California, Berkeley
- Bachelors Biochemistry University of California, Berkeley
Why Is Ivar Roots Influential?
(Suggest an Edit or Addition)Ivar Roots's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. (2000) (2528)
- Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. (1997) (1070)
- Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects (2001) (747)
- Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response (2004) (720)
- Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. (1999) (711)
- Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) (1999) (604)
- CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages (2001) (423)
- Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication (2007) (404)
- A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. (1996) (374)
- Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. (1996) (372)
- Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. (1995) (354)
- Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene (2002) (329)
- Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. (2003) (327)
- Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics (2004) (295)
- Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. (1999) (262)
- Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. (2003) (252)
- Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. (2002) (249)
- Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population (2003) (248)
- Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers (2002) (215)
- The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment (2002) (209)
- Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs (2005) (198)
- Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. (1997) (191)
- Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. (2000) (189)
- Genotype and Phenotype of Glutathione S-Transferase Class µ Isoenzymes µ and ψ in Lung Cancer Patients and Controls (1993) (187)
- Modulation of benzo[a]pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. (2000) (186)
- Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. (2000) (180)
- Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. (2003) (178)
- Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. (1994) (170)
- Effects of the CYP2D6 Gene Duplication on the Pharmacokinetics and Pharmacodynamics of Tramadol (2008) (169)
- Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant--463A of the myeloperoxidase gene. (2000) (169)
- Decreased Plasma Levels of Amitriptyline and Its Metabolites on Comedication With an Extract From St. John’s Wort (Hypericum perforatum) (2002) (167)
- Hydrogen peroxide in hepatic microsomes. (1978) (162)
- Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. (2003) (159)
- Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients (1999) (156)
- Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. (2003) (155)
- Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. (2000) (154)
- MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. (2002) (152)
- Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population (1999) (146)
- Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. (1996) (145)
- Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C‐[N‐3‐methyl]‐caffeine breath test in poor and extensive metabolizers of S‐mephenytoin (1992) (138)
- High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/Msp-GSTM1*0/*0 genotypes. (1998) (138)
- The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels (2001) (138)
- Hyperforin content determines the magnitude of the St John's Wort–cyclosporine drug interaction (2004) (136)
- Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin (1996) (135)
- Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants. (2001) (134)
- Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid. (2004) (134)
- l -Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism (2003) (131)
- Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol Pharmacokinetics and Pharmacodynamics (2004) (129)
- Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. (2000) (125)
- Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2 (2002) (122)
- Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol‐lowering activity of (−)‐3s,5r‐fluvastatin and (+)‐3r,5s‐fluvastatin in healthy volunteers (2003) (120)
- Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. (2003) (118)
- Genetic variants in FKBP5 affecting response to antidepressant drug treatment. (2008) (111)
- Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test (1994) (110)
- Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19 (2005) (104)
- Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class mu gene detected by polymerase chain reaction. (1992) (103)
- Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. (2003) (102)
- Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. (2001) (101)
- Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). (1999) (100)
- Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. (2000) (100)
- A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study (1999) (99)
- Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen. (2003) (96)
- Arylamine N-acetyltransferase activity in man. (1999) (95)
- Concordance between enzyme activity and genotype of glutathione S-transferase theta (GSTT1). (1998) (95)
- Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. (2001) (95)
- Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers. (1994) (93)
- Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphisms in patients with schizophrenia (2002) (93)
- Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. (2000) (92)
- No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. (2005) (91)
- Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region (1994) (91)
- Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia (2001) (90)
- Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. (2001) (90)
- Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone. (2005) (90)
- A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment (2007) (90)
- Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. (1988) (89)
- Correlation between serotonin uptake in human blood platelets with the 44-bp polymorphism and the 17-bp variable number of tandem repeat of the serotonin transporter. (2002) (89)
- Protective role of glutathione S-transferase P1 (GSTP1) Val105Val genotype in patients with bronchial asthma. (2003) (89)
- Possible control of hydrogen peroxide production and degradation in microsomes during mixed function oxidation reaction. (1973) (88)
- Specific and dose‐dependent enzyme induction by omeprazole in human beings (1994) (83)
- High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. (2000) (81)
- Deficiency of glutathione S-transferases T1 and M1 as heritable factors of increased cutaneous UV sensitivity. (1997) (81)
- Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. (1999) (79)
- Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. (2004) (78)
- Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers (2004) (78)
- MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. (2004) (78)
- Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. (1999) (77)
- Molecular Genetics of Cancer Susceptibility (2000) (75)
- Pitfalls in N-acetyltransferase 2 genotyping. (1999) (74)
- Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment (2008) (74)
- Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia (2000) (73)
- Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. (2003) (72)
- Pharmacodynamic Monitoring of Mycophenolate Mofetil (2000) (71)
- Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample. (2001) (70)
- Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. (1998) (69)
- MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes (2003) (68)
- Polymorphisms in xenobiotic conjugation and disease predisposition. (1998) (67)
- MDR1 Haplotypes Do Not Affect the Steady‐State Pharmacokinetics of Cyclosporine in Renal Transplant Patients (2003) (66)
- Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. (1987) (66)
- Implications of pharmacogenetics for individualizing drug treatment and for study design (2003) (65)
- Randomised, Double-Blind Study of the Effects of Oxybutynin, Tolterodine, Trospium Chloride and Placebo on Sleep in Healthy Young Volunteers (2003) (63)
- Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ≥ 50 years (2005) (63)
- Impact of Myeloperoxidase and NADPH-Oxidase Polymorphisms in Drug-Induced Agranulocytosis (2004) (63)
- St. John's wort extracts and some of their constituents potently inhibit ultimate carcinogen formation from benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1. (2003) (62)
- Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. (2002) (62)
- CYP2D6 Genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting (2000) (61)
- Vitamin D receptor haplotypes protect against development of colorectal cancer (2007) (60)
- Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics (2003) (60)
- Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. (2004) (59)
- Identification of six methylenetetrahydrofolate reductase (MTHFR) genotypes resulting from common polymorphisms: impact on plasma homocysteine levels and development of coronary artery disease. (2001) (59)
- In vitro assessment of inhibition by natural polyphenols of metabolic activation of procarcinogens by human CYP1A1. (2003) (59)
- Polymorphisms in the Human Cytochrome P-450 1A1 Gene (CYP1A1) as a Factor for Developing Acne (1998) (59)
- Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation. (1995) (59)
- Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu and Thr164Ile polymorphisms in the beta2-adrenergic receptor among Turks. (1999) (58)
- Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. (2000) (57)
- Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. (1996) (57)
- Pharmacokinetics of Levetiracetam in Patients with Moderate to Severe Liver Cirrhosis (Child‐Pugh Classes A, B, and C): Characterization by Dynamic Liver Function Tests (2005) (57)
- Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations (2008) (55)
- The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. (1992) (55)
- Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene (2003) (55)
- The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. (1999) (55)
- Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. (2003) (55)
- Impact of the CYP2D6 Ultrarapid Metabolizer Genotype on Mirtazapine Pharmacokinetics and Adverse Events in Healthy Volunteers (2004) (55)
- Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. (1999) (54)
- Flavin monooxygenase 3 (FMO3) polymorphism in a white population: Allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism (1999) (54)
- Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. (2001) (53)
- In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms (2006) (52)
- Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients. (1991) (51)
- Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls. (1993) (50)
- Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets (2005) (48)
- How to Manage Individualized Drug Therapy: Application of Pharmacogenetic Knowledge of Drug Metabolism and Transport (2000) (48)
- Functional analysis of the rat bile salt export pump gene promoter. (2002) (48)
- Determination and allelic allocation of seven nucleotide transitions within the arylamine N‐acetyltransferase gene in the Polish population (1996) (48)
- Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+-ATPase inhibitors and other xenobiotics (2003) (46)
- Pharmacokinetics of recombinant human erythropoietin after SC administration and in long-term IV treatment in patients on maintenance hemodialysis. (1989) (44)
- Simultaneous determination of ondansetron and tropisetron in human plasma using HPLC with UV detection. (2002) (44)
- High frequency of CYP1A1 mutations in a Turkish population (1998) (44)
- Paraoxonase 1 mutations in a Turkish population. (1999) (43)
- Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers (2009) (43)
- St John’s wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive (2009) (43)
- NAT2*12A (803A-->G) codes for rapid arylamine n-acetylation in humans. (1996) (42)
- Validity of PCR with emphasis on variable number of tandem repeat analysis. (2002) (41)
- St. John's wort and its constituent hyperforin concordantly regulate expression of genes encoding enzymes involved in basic cellular pathways (2005) (41)
- Determination of hyperforin, hypericin, and pseudohypericin in human plasma using high-performance liquid chromatography analysis with fluorescence and ultraviolet detection. (2001) (41)
- CYP1A1 genotype-selective inhibition of benzo[a]pyrene activation by quercetin. (2005) (40)
- Quantification of pravastatin in human plasma and urine after solid phase extraction using high performance liquid chromatography with ultraviolet detection. (2005) (40)
- Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn’s disease (2007) (40)
- The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. (2004) (39)
- Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS‐sorted peripheral blood CD4+, CD8+, CD19+, and CD56+cells (2003) (39)
- Nonlinear kinetics after high‐dose omeprazole caused by saturation of genetically variable CYP2C19 (1996) (39)
- Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. (1995) (38)
- CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? (2008) (38)
- Role of Kozak sequence polymorphism of platelet glycoprotein Ibalpha as a risk factor for coronary artery disease and catheter interventions. (2001) (38)
- Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene (2003) (38)
- Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probes. (2004) (38)
- Quantification of the antipsychotics flupentixol and haloperidol in human serum by high-performance liquid chromatography with ultraviolet detection. (1998) (37)
- A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer. (2003) (37)
- Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. (2000) (37)
- Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns. (2005) (36)
- Simultaneous determination of celecoxib, hydroxycelecoxib, and carboxycelecoxib in human plasma using gradient reversed-phase liquid chromatography with ultraviolet absorbance detection. (2003) (36)
- CYP1A1 mutations 4887A, 4889G, 5639C and 6235C in the Polish population and their allelic linkage, determined by peptide nucleic acid-mediated PCR clamping. (1997) (34)
- Oxidation and glucuronidation of valproic acid in male rats--influence of phenobarbital, 3-methylcholanthrene, beta-naphthoflavone and clofibrate. (1985) (34)
- Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer. (1996) (33)
- Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population. (1997) (33)
- Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro (2000) (32)
- Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection. (2003) (31)
- Pharmacogenetics‐Based New Therapeutic Concepts (2004) (31)
- Co-expression of human cytochrome P4501A1 (CYP1A1) variants and human NADPH-cytochrome P450 reductase in the baculovirus/ insect cell system (2001) (31)
- Polymorphic arylamine N‐acetyltransferase (NAT2) genes in children with insulin‐dependent diabetes mellitus (1994) (31)
- The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer. (2016) (30)
- Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers (2006) (30)
- Monitoring of pentobarbital plasma levels in critical care patients suffering from increased intracranial pressure. (1986) (30)
- Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus. (2002) (29)
- Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin’s cholesterol lowering capabilities and basal sterol serum levels (2006) (29)
- D-glucaric acid excretion in critical care patients--comparison with 6 beta-hydroxycortisol excretion and serum gamma-glutamyltranspeptidase activity and relation to multiple drug therapy. (1986) (29)
- Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. (2003) (29)
- Differential effects of Saint John's Wort (hypericum perforatum) on the urinary excretion of D-glucaric acid and 6β-hydroxycortisol in healthy volunteers (2002) (28)
- Influence of GSTT1 and GSTM1 Genotypes on Sunburn Sensitivity (2002) (27)
- Reduced procedural risk for coronary catheter interventions in carriers of the coagulation factor VII-Gln353 gene. (2000) (27)
- Elevated serum leptin in patients with coronary artery disease: no association with the Trp64Arg polymorphism of the β3-adrenergic receptor (2000) (27)
- Mono-oxygenase-Linked Hydrogen Peroxide Production and Degradation in Liver Microsomal Fractions (1975) (25)
- Determination of S-carboxymethyl-L-cysteine and some of its metabolites in urine and serum by high-performance liquid chromatography using fluorescent pre-column labelling. (1991) (25)
- Endothelin-1 Gene Variant Lys198Asn and Plasma Endothelin Level in Obstructive Sleep Apnea (2008) (25)
- Interaction of cyclosporin and calcium antagonists. (1989) (24)
- Effect of tolterodine on sleep structure modulated by CYP2D6 genotype. (2008) (24)
- Cytochrome P450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: Correlation with alprazolam pharmacokinetics (2003) (24)
- Association between the N-acetylation genetic polymorphism and bronchial asthma. (2002) (23)
- Evaluation ofin vivo parameters of drug metabolizing enzyme activity in man after administration of clemastine, phenobarbital or placebo (1975) (23)
- Detection of the GSTM1*0 allele by long polymerase chain reaction. (1999) (22)
- Clearance of ceftriaxone in critical care patients with acute renal failure (2005) (21)
- Human CYP1A1 allelic variants: baculovirus expression and purification, hydrodynamic, spectral, and catalytical properties and their potency in the formation of all-trans-retinoic acid. (2003) (21)
- Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. (1991) (21)
- A rare insertion of T226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15. (1996) (21)
- Inhibition of 17β-estradiol activation by CYP1A1: genotype- and regioselective inhibition by St. John's Wort and several natural polyphenols. (2011) (21)
- Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone (2005) (20)
- Rapid quantification of CYP3A4 expression in human leukocytes by real-time reverse transcription-PCR. (2002) (20)
- Neurotoxicity caused by a high cyclosporine metabolite level. (1989) (20)
- Below median birth weight in appropriate-for-gestational-age preterm infants as a risk factor for bronchopulmonary dysplasia (2008) (20)
- Prediction of aryl hydrocarbon receptor-mediated enzyme induction of drugs and chemicals by mRNA quantification. (1998) (19)
- Clinical Drug Interactions with Medicinal Herbs (2005) (19)
- Stoichiometric cooperation of NADPH and hexobarbital in hepatic microsomes during the catalysis of hydrogen peroxide formation. (1982) (19)
- Wort Extracts and Some of Their Constituents Potently Inhibit Ultimate Carcinogen Formation from Benzo [ a ] pyrene-7 , 8-Dihydrodiol by Human CYP 1 A 1 (2003) (18)
- Pharmacokinetic interaction between cyclosporin and diltiazem (2004) (18)
- Comparison of methods to study enzyme induction in man. (1975) (17)
- Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients (1992) (17)
- Association of NAT 1 and NAT 2 Polymorphisms to Urinary Bladder Cancer : Significantly Reduced Risk in Subjects with NAT 1 * 10 1 (2001) (16)
- IMMUNOSUPPRESSIVE PROPERTIES OF CYCLOSPORIN METABOLITES (1989) (16)
- Genetic polymorphisms in endothelin-receptor-subtype-a-gene as susceptibility factor for obstructive sleep apnea syndrome. (2010) (16)
- The β3-adrenergic receptor Trp64Arg mutation is not associated with coronary artery disease (2001) (16)
- A1166C polymorphism of the angiotensin II type 1 receptor gene and risk of adverse events after coronary catheter interventions. (2000) (15)
- Studies on the mechanism of stimulation of microsomal H2O2 formation and benzo(a)pyrene hydroxylation by substrates and flavone. (1981) (15)
- Genetic variants of the insulin receptor substrate‐1 are influencing the therapeutic efficacy of oral antidiabetics (2010) (15)
- Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers (2004) (15)
- Omeprazole weakly inhibits CYP1A2 activity in man. (1999) (15)
- Epoxidation of benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 in reconstituted membranes. Effects of charge and nonbilayer phase propensity of the membrane. (2002) (15)
- Peptide nucleic acid-mediated polymerase chain reaction clamping allows allelic allocation of CYP1A1 mutations. (1997) (14)
- The kinetics of metamizol and its metabolites in critical-care patients with acute renal dysfunction (2004) (14)
- Beta 2-adrenergic receptor polymorphism and susceptibility to primary congenital and primary open angle glaucoma (2003) (14)
- Interaction of CA repeat polymorphism of the endothelial nitric oxide synthase and hyperhomocysteinemia in acute coronary syndromes: evidence of gender-specific differences (2003) (14)
- Risk of coronary artery disease as influenced by variants of the human endothelin and endothelin-converting enzyme genes (2007) (12)
- Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients. (1998) (11)
- [Genetic causes for the variability of effects and side effects of drugs]. (1982) (11)
- Debrisoquine phenotyping in epileptic patients treated with phenytoin and carbamazepine (1985) (10)
- High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from subjects with combined CYP1A1 Mspl/Mspl and GSTM1*0/*0 genotypes (1997) (10)
- The beta3-adrenergic receptor Trp64Arg mutation is not associated with coronary artery disease. (2001) (9)
- Non-competitive and competitive inhibition of mixed function oxidase in rat liver microsomes by metyrapone (2004) (9)
- P XVI A.8 High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from subjects with combined CYP1A1 MspI/MspI-GSTM1*0/*0 genotypes (1997) (9)
- Hyperhomocysteinaemia and adverse events complicating coronary catheter interventions. (2000) (8)
- St John’s wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive (2009) (8)
- Acute poisoning with bromofosmethyl (bromophos). (1991) (8)
- Induction of CYP1A by various benzimidazoles and its significance in administrative drug regulation. (1999) (8)
- Kinetics of hexobarbital and dipyrone in critical care patients receiving high-dose pentobarbital (2004) (8)
- Antipyrine metabolite formation and excretion in patients with chronic renal failure (2004) (8)
- HPLC-ANALYSIS OF S-CARBOXYMETHYLCYSTEINE AND ITS SULPHOXIDE METABOLITES (1988) (8)
- Evaluation of proposed sulphoxidation pathways of carbocysteine in man by HPLC quantification (2004) (8)
- Activity of cyclosporin metabolites M17 and M1. (1990) (8)
- Vitamin D receptor poly(A) microsatellite and colorectal cancer risk in Caucasians (2009) (8)
- Association of C3435T and G2677T/A polymorphisms of multidrug resistance (MDR1) gene with colorectal cancer risk (2004) (7)
- Genotype and phenotype relationship in drug metabolism. (2007) (7)
- Dose dependent induction of CYP1A2 activity by omeprazole (Antra). (1992) (7)
- The Role of Pharmacogenetics in Drug Epidemiology (1987) (7)
- Urinary 6 beta-hydroxycortisol and D-glucaric acid excretion rates are not affected by lansoprazole treatment. (1997) (6)
- Pharmakogenetik als Basis neuer Therapiekonzepte (2003) (6)
- Systematic analysis of sequence variability of the endothelin-1 gene: a prerequisite for association studies. (2006) (6)
- Induction and inhibition of drug elimination in critical care patients as shown by pentobarbital and metamizol clearance (1985) (6)
- Epidemiological Concepts in Clinical Pharmacology (1987) (6)
- Evaluation of possible polymorphisms in sulfoxidation of carbocystein analysed by HPLC-methods (1990) (6)
- Identification of twelve polymorphisms in the endothelin-1 gene by use of fluorescently labeled oligonucleotides and PCR with restriction fragment polymorphism analysis. (2004) (5)
- Multiple‐dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to healthy volunteers (1991) (5)
- Hybrid information provided by the 14C-aminopyrine breath test studies with 14C-monomethylaminoantipyrine in the guinea pig (1980) (5)
- Recalling P446. P4501A1 (CYP1A1) Opting for Clinical Application (2007) (5)
- The platelet glycoprotein Ia C807T polymorphism as risk factor for coronary catheter interventions. (2000) (5)
- Impact of the CYP2D6 ultra‐rapid metabolizer genotype on CIS‐ and trans‐doxepin pharmacokinetics and serotonin concentration in platelets (2005) (5)
- Pharmacokinetics of Hypericin and Pseudohypericin after Oral Intake of the Hypericum Perforatum Extract LI 160 in Healthy Volunteers (1994) (4)
- The effect of the new immunosuppressive drug FK506 on the formation of secondary metabolites of cyclosporin A. (1992) (4)
- Assessment of Liver Metabolic Function Implications (1994) (4)
- Pharmacokinetics of temocapril and temocaprilat after 14 once daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment. (2003) (4)
- Demonstration of drug-ethanol interactions by changes in activity of hepatic microsomal oxidase/oxygenase cytochrome P-450 function. (1979) (3)
- Oral bioavailability of bromelain and trypsin after repeated oral administration of a commercial polyenzyme preparation (1996) (3)
- Enzyme catalysed cleavage of the N-N bond of N-nitrosamines. (1986) (3)
- Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin (1990) (3)
- A Single Nucleotide Polymorphism in the Human Hras Proto-oncogene Determines the Risk of Urinary Bladder Cancer 1 (2003) (3)
- The inhibitory effect of metyrapone on cytochrome P-450-catalyzed mixed-function oxidation reactions as compared to the effect of carbon monoxide. (1971) (3)
- A Polymorphism in Exon 7 of Human CYP 1 AJ : Population Frequency , Mutation Linkages , and Impact on Lung Cancer Susceptibility 1 (3)
- Determination of active centers of hepatic microsomal cytochrome P-450 by metyrapone, applying mutual depletion system kinetics. (1973) (3)
- MICROSOMAL ELECTRON TRANSPORT REACTIONS: THE FORMATION AND UTILIZATION OF HYDROGEN PEROXIDE AS RELATED TO ALCOHOL METABOLISM**Supported in part by a grant from the National Institutes of Health (5RO1-GM-16488). (1977) (3)
- Urinary excretion of D-glucaric acid, an indicator of drug metabolizing enzyme activity, in patients with impaired renal function. (1980) (3)
- Education in clinical pharmacology (1994) (2)
- Implication of arylamine N-acetyltransferase (NAT2) polymorphism on levels of tumour markers CEA, AFP, CA 125, CA 19.9, and CA 15.3 (1999) (2)
- Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study. (2010) (2)
- Fifteen polymorphisms in endothelin-1, endothelin-2 and endothelin-receptor-A genotyped by four duplex assays and seven simple assays on a LightCycler using hybridization probes (2006) (2)
- Polymerase chain reaction (PCR)-based construction of a competitor target for quantitative reverse transcriptase PCR measurement of cytochrome P450 1A1 mRNA. (1996) (2)
- Screening for abnormal cyclosporine A metabolite concentrations. (1989) (2)
- Theophylline metabolism affected by mexiletine (1992) (2)
- Promotion of B cell stimulation in graft recipients through a mechanism distinct from interleukin-6 gene superinduction. (1991) (2)
- Ml and Its Variants A and B as Host Factors of Bladder Cancer Susceptibility: A Case-Control Study (2006) (2)
- Single-dose pharmacokinetics of temocapril and temocapril diacid in subjects with varying degrees of renal impairment (1997) (2)
- Polymorphisms of toxifying and detoxifying hepatic enzymes in amyotrophic lateral sclerosis (2003) (2)
- [When is determination of drug concentrations in plasma useful or necessary?]. (1986) (2)
- Proceedings: Influence of haemo- and peritoneal dialysis on pharmacokinetics of diazoxide. (1975) (2)
- Determination of Glutathione S-Transferase u Genotype in Humans by PCR-Amplified Gene-Probes (1991) (2)
- Urinary excretion ofD-glucaric acid, an indicator of drug metabolizing enzyme activity, in patients with impaired renal function (1980) (2)
- 348 – Regulation of mechanism of oxygen and substrate function in hepatic microsomes (1978) (1)
- [Levosimendan. Clinical indications of a new vasoactive substance]. (2004) (1)
- The effects of substrates of mixed function oxidase on ethanol oxidation in rat liver microsomes (2004) (1)
- [Implications of pharmacogenetics in every-day practice]. (2005) (1)
- Comments from chairs of institutes of clinical pharmacology in Germany. (1994) (1)
- Polymorphisms of adrenergic receptors and the risk of heart failure. (2003) (1)
- Gene‐environment synergisms in bladder cancer risk: Arylamine n‐acetyltransferase type 2, smoking and occupation (1996) (1)
- Moxifloxacin does not Alter Ciclosporin Pharmacokinetics in Transplant Patients (2012) (1)
- An anomalous haplotype distribution of the arrestin domain-containing 4 gene (ARRDC4) haplotypes in Caucasians. (2008) (1)
- Rapid genotyping of melanocortin-1 receptor with use of fluorescence-labeled oligonucleotides. (2003) (1)
- Benzo(a)pyrene metabolism in hepatic microsomes from female DA rats with a genetic sparteine oxidation deficiency. (1985) (1)
- Proceedings: Stimulation of microsomal ethanol oxidation by H202 formation during the uncoupling of hepatic microsomal mixed function oxidation reactions. (1975) (1)
- Cyclosporin drug monitoring: Comparison of four immunoassays and HPLC (1989) (1)
- The G protein subunit beta3 and early complications after coronary catheter interventions. (2000) (1)
- [Pharmacogenetic implications of transmembrane transporters for the uptake, distribution and excretion of drugs]. (2003) (1)
- Active centers of microsomal cytochrome P-450 determined with metyrapone by mutual depletion system kinetics (2004) (1)
- [The value of pharmacogenetic tests in antidepressive medication therapy]. (2005) (1)
- Influence of CYP2C9 amino acid polymorphisms on enantioselective metabolism of R‐,S‐phenprocoumon (2003) (0)
- Genetic Variability: Implications for Toxicogenomic Research (2005) (0)
- Short Communication A Single Nucleotide Polymorphism in the Human H-ras Proto-oncogene Determines the Risk of Urinary Bladder Cancer 1 (2003) (0)
- The polymorphic enzymes N-acetyltransferase 2 and glutathione S-transferase M1 In bladder cancer patients (1997) (0)
- CYP1A1 alleles in women with focal nodular hyperplasia of the liver (FNH). (2004) (0)
- Molekulare Pathologie (2000) (0)
- Enantio‐preferential effects of the CYP2D6 genotype on bioavailability and systemic clearance of the tricyclic antidepressant trimipramine (2004) (0)
- Use of hypericin and / or its derivatives for tumor prevention (2002) (0)
- Slow N-acetylation phenotype in urothellal cancer patients (1995) (0)
- Variations i n t he 5 -Hydroxytryptam ine T ype 3 B R eceptor G ene as P redictors o f t he E fficacy o f A ntiemetic T reatment i n Cancer P atients (2003) (0)
- [Clinical relevance of acetylator phenotyping in 196 urothelial tumor patients]. (1997) (0)
- Breast cancer and vitamin D receptor polymorphism (1999) (0)
- Variability of bupropion pharmacokinetics in relation to amino acid polymorphisms in CYP2B6 (2003) (0)
- Debrisoquine hydroxylation polymorphism: comparison of debrisoquine- and dextromethorphan-test and restriction fragment analysis in healthy volunteers (1990) (0)
- Frequency of Cyp2D6, 2C9, 2C19 polymorphisms in depressive and schizophrenic patients (2004) (0)
- Thepharmacokinetics andpharmacodynamics ofrecombinant humanerythropoietin inhaemodialysis patients (1992) (0)
- [Adverse drug effects and interactions. What is the current thinking about the use of St. John's wort?]. (2003) (0)
- Proceedings: Evaluation of induction of drug metabolizing enzyme activities in man by different in vivo tests. (1974) (0)
- 4. Genetik-Workshop des Robert Koch-Instituts 2/99 in Berlin (1999) (0)
- Molecular-epidemiological aspects of carcinogenesis: the role of xenobiotic metabolizing enzymes. (2002) (0)
- ALTERATIONS OF OXIDATIVE DRUG METABOLISM IN CRITICAL-CARE PATIENTS (1986) (0)
- [Micromethod for determination of amrinone and acetylamrinone in plasma and urine with HPLC]. (1994) (0)
- [Fundamentals of drug therapy: antacids--laxatives]. (1974) (0)
- gen polymorphism in the human MDR-1 and its use (2000) (0)
- The therapeutic effect of betamethasone for prenatal lung maturation in very low birthweight infants may be influenced by maternal and fetal ABCB1-polymorphism – A pilot study (2011) (0)
- Pharmacogenetic studies on drug-metabolizing cytochromes P450 and possibilities for individual drug therapy (2002) (0)
- 58 – MODIFICATION OF ETHANOL METABOLISM BY ETHYLMORPHINE (EM) VIA DIFFERENT REACTIONS (1978) (0)
- Variability in the pharmacokinetics of R‐(−)‐ and S‐(+)‐mirtazapine in dependence of the CYP2D6 genotype (2005) (0)
- On the impact of the CYP2D6 ultra‐rapid metabolizer genotype on mirtazapine pharmacokinetics (2004) (0)
- Interaction of Calcium Antagonists and Ciclosporine A (1989) (0)
- Proceedings: H2O2 formation during the uncoupling of hepatic microsomal mixed function oxidation reactions. Its relation to ethanol oxidation. (1975) (0)
- N-acetyltransferase 2 and glutathione-S-transferase μ (GSTM1) in bladder cancer patients in an area of former coal, iron and steel industries (1996) (0)
- The role of myeloperoxidase and NADPH oxidase polymorphisms in clozapine-induced agranulocytosis (2004) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ivar Roots?
Ivar Roots is affiliated with the following schools:
